Events & Presentations

Investors

Events & Presentations

Upcoming Events
Date Event Details Remind Me
Nov 18, 2019
American Heart Association Scientific Sessions 2019

November 18, 9:32 a.m. EST – Dr. Christie Ballantyne, Baylor Coll Med, Houston, TX, will deliver an oral presentation titled, “RNA Interference Targeting Apolipoprotein C-III Results in Deep and Prolonged Reductions in Plasma Triglycerides”

November 18, 9:38 a.m. EST – Dr. Gerald Watts, Univ of Western Australia, Royal Perth Hosp, Perth, Australia, will deliver an oral presentation titled, “RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects”

Philadelphia
Nov 25, 2019 4:30 PM EST
Arrowhead Pharmaceuticals 2019 Year End Results
Archived Events
Date Event Details
Jan 8 - Jan 10, 2018 12:00 AM EST
JP Morgan Healthcare Conference Week
Dec 12, 2017 4:30 PM EST
Arrowhead Pharmaceuticals 2017 Fiscal Year End Results
Dec 5, 2017 6:10 PM HST
HEP DART 2017
Kona, Hawaii
Nov 28, 2017 9:30 AM EST
29th Annual Piper Jaffray Healthcare Conference
Nov 13 - Nov 15, 2017 12:00 AM EST
BIT's 8th World Gene Convention-2017
Macau, China
Oct 23, 2017
The Liver Meeting® 2017, the Annual Meeting of the American Association for the Study of Liver Disease
Washington, DC

Subcutaneous delivery of a RNA interference (RNAi) therapeutic candidate for alpha-1 antitrypsin deficiency (AATD)-related liver disease produces deep and prolonged knockdown of plasma AAT

  • Publication Number: LB-21
  • Session: Late-Breaking Poster Session
  • Session Date and Time: October 23, 2017 from 8:00 AM to 5:30 PM

·        Authors: Christine I. Wooddell, et al.

Oct 10, 2017 10:45 AM EDT
Chardan Gene Therapy Conference
Sep 25, 2017 9:10 AM EDT
2017 Cantor Fitzgerald Global Healthcare Conference
Sep 14, 2017 1:00 PM EDT
Arrowhead Analyst R&D Day
Aug 3, 2017 4:30 PM EDT
Arrowhead Fiscal 2017 Third Quarter Results